FDA reviewers raised no major safety questions about the Galleri cancer blood test, but the agency’s own data show it missed most stage I cancers.
Galleri Blood Test Draws No Major Safety Questions From FDA Staff, but It Missed Most Stage I Cancers
by | Sep 22, 2026 | Uncategorized | 0 comments

Recent Comments